Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas

Epigenetics

Volumn 11, Issue 3, 2016, Pages 184-193

  Kleb, Brittany ^a   Estécio, Marcos R H ^b   Zhang, Jiexin ^a   Tzelepi, Vassiliki ^c   Chung, Woonbok ^d   Jelinek, Jaroslav ^d   Navone, Nora M ^a   Tahir, Salahaldin ^a   Marquez, Victor E ^e   Issa, Jean Pierre ^d   Maity, Sankar ^a   Aparicio, Ana ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF PATRAS   (Greece)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Androgen receptor; DNA methylation; epigenetics; EZH2; histone methylation; neuroendocrine; prostate cancer; small cell prostate carcinoma; xenograft

Indexed keywords

ANDROGEN RECEPTOR; 3-DEAZANEPLANOCIN; ADENOSINE; EZH2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR EZH2;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; EPIGENETICS; GENE AMPLIFICATION; GENE EXPRESSION; GENE SILENCING; HISTONE MODIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN METHYLATION; PYROSEQUENCING; TUMOR XENOGRAFT; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL LINEAGE; DNA METHYLATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; MOUSE; PATHOLOGY; PROMOTER REGION; SMALL CELL CARCINOMA; TUMOR CELL LINE;

ADENOSINE; ANIMALS; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; CELL LINEAGE; CPG ISLANDS; DNA METHYLATION; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84961393163     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.1080/15592294.2016.1146851     Document Type: Article

References (33)

1. C.J.Ryan, A.Molina, J.Li, T.Kheoh, E.J.Small, C.M.Haqq, R.P.Grant, J.S.de Bono, H.I.Scher. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol 2013; 31(22): p:2791-8; PMID:23816964; http://dx.doi.org/10.1200/JCO.2012.45.4595
2. D.Rathkopf, H.I.Scher. Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J 2013; 19(1): p:43-9; PMID:23337756; http://dx.doi.org/10.1097/PPO.0b013e318282635a
3. M.Tanaka, Y.Suzuki, K.Takaoka, N.Suzuki, S.Murakami, O.Matsuzaki, J.Shimazaki. Progression of prostate cancer to neuroendocrine cell tumor. Int J Urol 2001; 8(8): p:431-6; discussion 437; PMID:11555007; http://dx.doi.org/10.1046/j.1442-2042.2001.00347.x
4. S.R.Moore, Y.Reinberg, G.Zhang, Small cell carcinoma of prostate: effectiveness of hormonal versus chemotherapy. Urology 1992; 39(5):p:411-6; PMID:1315995; http://dx.doi.org/10.1016/0090-4295(92)90235-O
5. C.N.Papandreou, D.D.Daliani, P.F.Thall, S.M.Tu, X.Wang, A.Reyes, P.Troncoso, C.J.Logothetis. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002; 20(14): p:3072-80; PMID:12118020; http://dx.doi.org/10.1200/JCO.2002.12.065
6. J.Y.Ro, B.Têtu, A.G.Ayala, N.G.Ordóñez. Small cell carcinoma of the prostate. II. Immunohistochemical and electron microscopic studies of 18 cases. Cancer 1987; 59(5):p:977-82; PMID:2434204; http://dx.doi.org/10.1002/1097-0142(19870301)59:5<977::AID-CNCR2820590521>3.0.CO;2-G
7. A.Aparicio, V.Tzelepi, J.C.Araujo, C.C.Guo, S.Liang, P.Troncoso, C.J.Logothetis, N.M.Navone, S.N.Maity. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate 2011; 71(8): p:846-56; PMID:21456067; http://dx.doi.org/10.1002/pros.21301
8. V.Tzelepi, J.Zhang, J.F.Lu, B.Kleb, G.Wu, X.Wan, A.Hoang, E.Efstathiou, K.Sircar, N.M.Navone, et al. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res 2012; 18(3): p:666-77; PMID:22156612; http://dx.doi.org/10.1158/1078-0432.CCR-11-1867
9. N.Clegg, C.Ferguson, L.D.True, H.Arnold, A.Moorman, J.E.Quinn, R.L.Vessella, P.S.Nelson. Molecular characterization of prostatic small-cell neuroendocrine carcinoma. Prostate 2003; 55(1): p:55-64; PMID:12640661; http://dx.doi.org/10.1002/pros.10217
10. A.V.Lapuk, C.Wu, A.W.Wyatt, A.McPherson, B.J.McConeghy, S.Brahmbhatt, F.Mo, A.Zoubeidi, S.Anderson, R.H.Bell, et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol 2012; 227(3): p:286-97; PMID:22553170; http://dx.doi.org/10.1002/path.4047
11. A.Meissner, T.S.Mikkelsen, H.Gu, M.Wernig, J.Hanna, A.Sivachenko, X.Zhang, B.E.Bernstein, C.Nusbaum, D.B.Jaffe, et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 2008; 454(7205): p:766-70; PMID:18600261; http://dx.doi.org/10.1038/nature07107
12. N.M.Navone, M.Olive, P.Troncoso. Isolation and culture of prostate cancer cell lines. Methods Mol Med, 2004; 88: p:121-32; PMID:14634223; http://dx.doi.org/10.1385/1-59259-406-9:121
13. Z.G.Li, P.Mathew, J.Yang, M.W.Starbuck, A.J.Zurita, J.Liu, C.Sikes, A.S.Multani, E.Efstathiou, A.Lopez, et al. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest 2008; 118(8): p:2697-710; PMID:18618013; http://dx.doi.org/10.1172/JCI33637C1
14. W.Tang, F.B.David, M.M.Wilson, B.G.Barwick, B.R.Leyland-Jones, M.M.Bouzyk. DNA extraction from formalin-fixed, paraffin-embedded tissue. Cold Spring Harb Protoc 2009; 2009(2): p:pdb prot5138; PMID:20147068; http://dx.doi.org/10.1101/pdb.prot5138
15. K.T.Flaherty, I.Puzanov, K.B.Kim, A.Ribas, G.A.McArthur, J.A.Sosman, P.J.O'Dwyer, R.J.Lee, J.F.Grippo, K.Nolop, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med, 2010; 363(9): p:809-19; PMID:20818844; http://dx.doi.org/10.1056/NEJMoa1002011
16. M.Toyota, C.Ho, M.Ohe-Toyota, S.B.Baylin, J.P.Issa. Inactivation of CACNA1G, a T-type calcium channel gene, by aberrant methylation of its 5′ CpG island in human tumors. Cancer Res 1999; 59(18): p:4535-41; PMID:10493502
17. M.R.Estecio, P.S.Yan, A.E.Ibrahim, C.S.Tellez, L.Shen, T.H.Huang, J.P.Issa. High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res 2007; 17(10): p:1529-36; PMID:17785535; http://dx.doi.org/10.1101/gr.6417007
18. Yang YH, Dudoit S, Luu P, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic acids research 2002; 30(4):e15; PMID:11842121; http://dx.doi.org/10.1093/nar/30.4.e15
19. S.Colella, L.Shen, K.A.Baggerly, J.P.Issa, R.Krahe. Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques, 2003; 35(1): p:146-50; PMID:12866414
20. L.Shen, M.Toyota, Y.Kondo, E.Lin, L.Zhang, Y.Guo, N.S.Hernandez, X.Chen, S.Ahmed, K.Konishi, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A 2007; 104(47): p:18654-9; PMID:18003927; http://dx.doi.org/10.1073/pnas.0704652104
21. Z.G.Li, J.Yang, E.S.Vazquez, D.Rose, F.Vakar-Lopez, P.Mathew, A.Lopez, C.J.Logothetis, S.H.Lin, N.M.Navone. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene 2008; 27(5): p:596-603; PMID:17700537; http://dx.doi.org/10.1038/sj.onc.1210694
22. R.A.Irizarry, C.Ladd-Acosta, B.Wen, Z.Wu, C.Montano, P.Onyango, H.Cui, K.Gabo, M.Rongione, M.Webster, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009; 41(2): p:178-86; PMID:19151715; http://dx.doi.org/10.1038/ng.298
23. M.Chu, Y.Chang, P.Li, Y.Guo, K.Zhang, W.Gao. Androgen receptor is negatively correlated with the methylation-mediated transcriptional repression of miR-375 in human prostate cancer cells. Oncol Rep 2014; 31(1): p:34-40; PMID:24173286; http://dx.doi.org/10.1038/sj.onc.1210694
24. S.Yegnasubramanian, J.Kowalski, M.L.Gonzalgo, M.Zahurak, S.Piantadosi, P.C.Walsh, G.S.Bova, A.M.De Marzo, W.B.Isaacs, W.G.Nelson. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004; 64(6): p:1975-86; PMID:15026333; http://dx.doi.org/10.1158/0008-5472.CAN-03-3972
25. S.Varambally, S.M.Dhanasekaran, M.Zhou, T.R.Barrette, C.Kumar-Sinha, M.G.Sanda, D.Ghosh, K.J.Pienta, R.G.Sewalt, A.P.Otte, et al., The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419(6907): p:624-9; PMID:12374981; http://dx.doi.org/10.1038/nature01075
26. P.A.Jones, G.Liang. Rethinking how DNA methylation patterns are maintained. Nat Rev Genet 2009; 10(11): p:805-11; PMID:19789556; http://dx.doi.org/10.1038/nrg2651
27. A.M.Aparicio, A.L.Harzstark, P.G.Corn, S.Wen, J.C.Araujo, S.M.Tu, L.C.Pagliaro, J.Kim, R.E.Millikan, C.Ryan, et al., Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 2013; 19(13): p:3621-30; PMID:23649003; http://dx.doi.org/10.1158/1078-0432.CCR-12-3791
28. Aparicio AM, Shen L, Tapia EL, et al. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clinical cancer research 2015; PMID:26546618; http://dx.doi.org/10.1158/1078-0432.CCR-15-1259
29. J.Tan, X.Yang, L.Zhuang, X.Jiang, W.Chen, P.L.Lee, R.K.Karuturi, P.B.Tan, E.T.Liu, Q.Yu. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007; 21(9): p:1050-63; PMID:17437993; http://dx.doi.org/10.1101/gad.1524107
30. T.B.Miranda, P.A.Jones. DNA methylation: the nuts and bolts of repression. J Cell Physiol 2007; 213(2): p:384-90; PMID:17708532; http://dx.doi.org/10.1002/jcp.21224
31. N.P.McCabe, S.De, A.Vasanji, J.Brainard, T.V.Byzova. Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. Oncogene 2007; 26(42): p:6238-43; PMID:17369840; http://dx.doi.org/10.1038/sj.onc.1210429
32. Y.Niu, S.Altuwaijri, K.P.Lai, C.T.Wu, W.A.Ricke, E.M.Messing, J.Yao, S.Yeh, C.Chang. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci U S A 2008; 105(34): p:12182-7; PMID:18723679; http://dx.doi.org/10.1073/pnas.0804700105
33. Q.Wang, W.Li, Y.Zhang, X.Yuan, K.Xu, J.Yu, Z.Chen, R.Beroukhim, H.Wang, M.Lupien, et al., Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009; 138(2): p:245-56; PMID:19632176; http://dx.doi.org/10.1016/j.cell.2009.04.056